Lupus

On June 13, the U.S. Supreme Court rejected a lawsuit that challenged the FDA’s approach to regulating the abortion pill mifepristone.

Belimumab substantially increases circulating memory B-cells in patients with systemic lupus erythematosus, potentially enabling “a more efficient targeting of the B-cell compartment,” according to data published in Rheumatology.

Juvenile arthritis can impact the physical and emotional wellbeing of children in unique ways, manifesting in loneliness and depression, according to the Arthritis Foundation.

Early use of biologics like belimumab may limit complications associated with steroid use and improve long-term outcomes in systemic lupus erythematosus, according to data presented at the EULAR 2024 Congress.

Reducing steroids in favor of more targeted therapies can minimize organ damage in pediatric systemic lupus erythematosus, according to data presented at EULAR 2024 Congress.

Patients with lupus nephritis who receive higher initial doses of glucocorticoids demonstrate improved renal outcomes, albeit with increased serious infection and mortality risks, according to data published in Arthritis & Rheumatology.

Treatment with belimumab resulted in fewer flares in patients with either early or established systemic lupus erythematosus, especially among those with no baseline organ damage, according to data presented at the EULAR 2024 Congress.

Deucravacitinib is “very likely to be the best” targeted small-molecule drug for the treatment of systemic lupus erythematosus, according to data published in Arthritis Research & Therapy.

New definitions of remission specific to childhood systemic lupus erythematosus promote cessation of corticosteroids and could enable combined child-adult treat-to-target studies, according to an analysis published in Clinical Immunology.

CLEVELAND — While new treatments for cutaneous lupus are on the horizon, sunscreen remains the best way to offset effects, according to J. Michelle Kahlenberg, MD, PhD.